Intestinal microbiota balance modulates host susceptibility to infection with enteric pathogens
Inna Sekirov is a 5th year MD/PhD student at the University of British Columbia, currently in her 3rd year of research. She works in the laboratory of Dr. B. Brett Finlay, studying the contribution of the intestinal bacterial microbiota, i.e. the normal flora, to the progression of the enteric infectious diseases and to the host susceptibility to enteric pathogens. Next September she is planning to defend her PhD thesis and return to 3rd year Medicine and, upon graduation, to pursue a residency in either laboratory or internal medicine. Her main research interests include investigating the molecular mechanisms associated with therapeutic resistance and recurrence in patients suffering from the most common primary brain tumor, Glioblastoma Multiforme. Upon completion of her PhD, Ampaso plans to return to medicine with the goal of pursuing a residency in neurosurgery.
Mast cells release cytokines in

Gene transfer of endothelial Nosynthase restores migratory capacity of endothelial progenitor cells from patients with coronary artery disease
Mike Ward is in his 4 th year of the MD/PhD program at the University of Toronto and working under the supervision of two clinician scientists in cardiology, Dr. Duncan Stewart and Dr. Michael Kutryk. Generally, their work involves developing cell-based therapies for cardiovascular diseases, and our group currently is running a clinical trial of autologous cellbased gene therapy for pulmonary arterial hypertension, while preparing a similar trial for acute myocardial infarction. Mike's project deals specifically with addressing a caveat of autologous cell therapy in the clinical arena, that is, the endothelial progenitor cell (EPC) dysfunction found in patients suffering from coronary disease and atherosclerotic risk factors. This EPC dysfunction could explain the disappointing reports from clinical trials following very exciting results from preclinical models. He is employing gene transfer technology to attempt to overcome this dysfunction and hopefully improve the efficacy of autologous cell therapy following acute MI. Mike is also the President of the Clinician Investigator Trainee Association of Canada (CITAC), which is currently developing a database of MD+ trainees in Canada and establishing a national mentorship program in association with the CSCI. He hopes that CITAC will grow to become a strong advocating body for MD+ trainees across the country.
Targeted deletion of discoidin domain receptor 1 decreases atherosclerosis, reduces inflammation and accelerates matrix accumulation in LDL receptor deficient mice
Chris Franco is currently in his fifth year of the MD/PhD program at the University of Toronto working under the supervision of Dr. Michelle Bendeck. His research involves investigating the role of a novel collagen receptor, the discoidin domain receptor 1 (Ddr1), in the pathogenesis of atherosclerosis. Chris' work with hypercholesterolemic mice has identified DDR1 as a positive regulator of atherogenesis. Deletion of DDR1 caused a persistent reduction in atherosclerotic plaque development and resulted in the formation of macrophage poor lesions that were abundant in extracellular matrix. Chris' future studies will attempt to further dissect the role of DDR1 in the regulation of fibrosis and chronic inflammation during atherosclerosis using bone marrow transplantation. After graduation, Chris hopes to pursue a residency in pathology and begin his career as a clinician-scientist.
